Cargando…

Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study

EVIDENS is an ongoing, prospective, non-interventional study evaluating the effectiveness and safety of nivolumab in lung cancer patients in France (ClinicalTrials.gov NCT03382496). Adults with a pathologically confirmed diagnosis of lung cancer and initiating treatment with nivolumab were recruited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barlesi, Fabrice, Dixmier, Adrien, Debieuvre, Didier, Raspaud, Christophe, Auliac, Jean-Bernard, Benoit, Nicolas, Bombaron, Pierre, Moro-Sibilot, Denis, Audigier-Valette, Clarisse, Asselain, Bernard, Egenod, Thomas, Rabeau, Audrey, Fayette, Jérôme, Sanchez, Myriam Locatelli, Labourey, Jean-Luc, Westeel, Virginie, Lamoureux, Pauline, Cotte, François-Emery, Allan, Victoria, Daumont, Melinda, Dumanoir, Juliette, Reynaud, Dorothée, Calvet, Christophe Yannick, Ozan, Nicolas, Pérol, Maurice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Back Matter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790497/ https://www.ncbi.nlm.nih.gov/pubmed/33457089 http://dx.doi.org/10.1080/2162402X.2020.1744898

Ejemplares similares

Real-life experience of ceritinib in crizotinib-pretreated ALK(+) advanced non-small cell lung cancer patients
por: Cadranel, Jacques, et al.
Publicado: (2018)

Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): Results of three French consecutive nationwide prospective cohorts’ studies
por: Debieuvre, Didier, et al.
Publicado: (2022)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Effectiveness of Nivolumab in Second-Line and Later in Patients with Advanced Non-Small Cell Lung Cancer in Real-Life Practice in France and Germany: Analysis of the ESME-AMLC and CRISP Cohorts
por: Chouaid, Christos, et al.
Publicado: (2022)

IFCT-1502 CLINIVO: real-world evidence of long-term survival with nivolumab in a nationwide cohort of patients with advanced non-small-cell lung cancer
por: Molinier, O., et al.
Publicado: (2021)

Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
por: Herbreteau, Guillaume, et al.
Publicado: (2020)

Proposals for managing patients with thoracic malignancies during COVID-19 pandemic
por: Girard, N., et al.
Publicado: (2020)

Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
por: Baldacci, Simon, et al.
Publicado: (2017)

Survival inequalities in patients with lung cancer in France: A nationwide cohort study (the TERRITOIRE Study)
por: Chouaïd, Christos, et al.
Publicado: (2017)

First-line management of advanced non-small-cell lung cancer: can we do better?
por: Chouaïd, Christos, et al.
Publicado: (2023)

Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma
por: Bylicki, Olivier, et al.
Publicado: (2020)

Access to innovative drugs for metastatic lung cancer treatment in a French nationwide cohort: the TERRITOIRE study
por: Scherpereel, Arnaud, et al.
Publicado: (2018)

Management of lung cancer patients' quality of life in clinical practice: a Delphi study
por: Westeel, V., et al.
Publicado: (2021)

Staging of nutrition disorders in non‐small‐cell lung cancer patients: utility of skeletal muscle mass assessment
por: Antoun, Sami, et al.
Publicado: (2019)

Biocorrosion on Nanofilms Induces Rapid Bacterial Motions via Iron Dissolution
por: Lherbette, Marion, et al.
Publicado: (2021)

Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study
por: Duruisseaux, Michaël, et al.
Publicado: (2017)

Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)
por: Thureau, Sébastien, et al.
Publicado: (2021)

Pneumatocoeles after bronchoscopic lung volume reduction with valves
por: Lestelle, Francois, et al.
Publicado: (2021)

Women and COPD: do we need more evidence?
por: Gut-Gobert, Christophe, et al.
Publicado: (2019)

MSH2/BRCA1 expression as a DNA-repair signature predicting survival in early–stage lung cancer patients from the IFCT-0002 Phase 3 Trial
por: Levallet, Guénaëlle, et al.
Publicado: (2016)

Impact of a visual indicator on the noise level in an emergency medical dispatch centre - a pilot study
por: Outrey, Justin, et al.
Publicado: (2021)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
por: Remon, Jordi, et al.
Publicado: (2020)

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study
por: Girard, N., et al.
Publicado: (2022)

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes
por: Ruppert, Anne-Marie, et al.
Publicado: (2020)

Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study
por: Toffart, Anne-Claire, et al.
Publicado: (2014)

Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504)
por: Christos, Chouaid, et al.
Publicado: (2012)

Omicron variant: A clear and present danger for patients with cancer
por: Barrière, J., et al.
Publicado: (2022)

Préconisations pour protéger les patients de la filière oncologique face au variant Omicron
por: Barrière, Jérôme, et al.
Publicado: (2022)

Survival outcomes of patients with metastatic non-small cell lung cancer receiving chemotherapy or immunotherapy as first-line in a real-life setting
por: Belaroussi, Yaniss, et al.
Publicado: (2023)

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
por: Descourt, Renaud, et al.
Publicado: (2022)

General topology
por: Dixmier, Jacques
Publicado: (1984)

Von Neumann algebras
por: Dixmier, Jacques
Publicado: (1981)

Les algebres d'opérateurs dans l'espace hilbertien: (algebres de Von Neumann)
por: Dixmier, Jacques
Publicado: (1957)

Algèbres de Lie: rédaction de A. Pereira Gomes
por: Dixmier, Jacques
Publicado: (1962)

Enveloping algebras
por: Dixmier, Jacques
Publicado: (1996)

A phase Ia/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol
por: Elharrar, Xavier, et al.
Publicado: (2016)

Comorbidities of COPD
por: Cavaillès, Arnaud, et al.
Publicado: (2013)

Impact of Adjuvant Chemotherapy on Breast Cancer Survival: A Real-World Population
por: Rossi, Lea, et al.
Publicado: (2015)

Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small–Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study)
por: Auliac, Jean-Bernard, et al.
Publicado: (2020)

Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
por: Bennouna, Jaafar, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0mhg2gadpdt4m8b2ksj3ieq7m3